The Pharma and Biotech Patent Litigation North America

Pharma and Biotech Patent Litigation USA 2025 (November 18-19, 2025 - Philadelphia Marriott Downtown) is the leading event focused exclusively on patent litigation across the life sciences sector. Returning for it's second year join over 350 litigation leaders, in-house counsel, and private practice experts as we navigate the evolving legal, regulatory, and commercial pressures impacting IP strategy in the pharmaceutical and biotech industries.

No other event in this space brings together a 50% in-house counsel audience, giving you a direct line to the decision-makers shaping patent litigation strategy at companies including Moderna, Regeneron, Teva, Fresenius Kabi, and BioNTech. Whether you're managing biosimilar disputes, Hatch-Waxman litigation, or cross-border patent enforcement, this is the place to benchmark with your peers and gain insights you won't find elsewhere.

What's New for 2025?

Safe Harbor and Enablement Updates:
Understand how recent case law is redrawing the boundaries of § 271(e)(1), and what the latest enablement rulings mean for life sciences patents post-Amgen v. Sanofi.

AI, Inventorship, and Litigation Risk:
Explore how AI-driven discovery is impacting inventorship definitions, IP ownership, and the likelihood of disputes in the coming years.

The Unified Patent Court in Focus:
Assess how US-based companies should factor UPC rulings and enforcement options into their cross-border litigation strategy.

Branded vs. Branded Litigation Trends:
Dive into the emerging wave of originator-on-originator disputes, from Humira to Covid-19-related cases.

New Judicial Perspectives:
Hear directly from sitting and former judges across the Federal Circuit, Pennsylvania, New Jersey, and Delaware on shifting litigation dynamics and venue strategy.

Interactive Roundtables and Strategy Deep Dives:
Get involved in sessions covering global third-party discovery, MDLs, biologics strategy, patent/regulatory alignment, and European oppositions.

Quote 'EVNNT10' to claim 10% off your registration.

Speakers: Monica Baig Silva, VP IP, Thermo Fisher, Christof Bull, Assistant General Patent Counsel, UCB, Mathilde Rauline, Head of Greater Europe Patent Litigation, Sanofi, Leslie Fischer, Principal Patent Attorney, Sandoz, Ewan Nettleton, Principal IP Counsel - Oncology Litigation, Novartis, Shohta Ueno, Assistant General Counsel - Dispute Resolution, Regeneron, Stephan Kutik, Director Intellectual Property, Genevant Sciences, Julia Pike, Global Head of IP, Sandoz, Paki Banky, Senior IP Counsel (IP Lead Cell and Gene), Novartis, Corinna Sundermann, Senior Vice President Intellectual Property, Fresenius Kabi, Phil Caramanica, Chief IP Counsel, Alvotech, James Horgan, Chief IP Counsel - Policy and Litigation, MSD, Kristin Cooklin, Global Head IP Counsel, Recordati, Kim Jessum, VP Legal, Heraeus Medical, Christine P. O'Hearn, Hon. Judge, US District Court, District of New Jersey, Renée Marie Bumb, Chief District Judge, US District Court, District of New Jersey, Paul Michel, Ex-Chief Judge, US Federal Circuit, Mitchell Goldberg, Chief District Judge, US District Court, Eastern District of Pennsylvania, Damon Gupta, Director, Patent Counsel, Spark Therapeutics, Inc., Kevin Yurkerwich, Senior IP Counsel, Novartis, Alison Kessler, VP Corporate Legal Corporate and IP, Solid Biosciences, Andrea Tiglio, Assistant General Counsel, Jazz Pharma, Matthew Blischak, CEO, Finch Therapeutics, Fahd Majiduddin, Senior IP Litigation Counsel, Sandoz, Don Huddler, Assistant General Counsel, GSK, Lauren Rabinovic, VP - IP Litigation, Moderna, Sergio Napolitano, General Counsel, Medicines for Europe, Eva Ehlich, Partner, Maiwald, Eric Dittmann, Partner, Paul Hastings, Sanjaya Mendis, Partner, McCarthy Tetrault, Robin Ellis, Partner, Reddie and Grose, Gareth Morgan, Partner, Pinsent Masons, Jonathan Newdorf, Senior Director, RWS